Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PathoQuest and Covance to Offer NGS-based Biosafety Assessments

Published: Thursday, November 07, 2013
Last Updated: Wednesday, November 06, 2013
Bookmark and Share
Unique technology for virus screening in a single comprehensive assay to overcome the current limitations with predefined sets of known viruses.

Covance Inc. and PathoQuest have announced an exclusive agreement to collaborate in providing Next-Generation Sequencing (NGS) based biosafety assessments.

This innovative biosafety testing approach, combined with Covance’s regulatory expertise, provides a flexible testing solution to all biotherapeutic clients and makes biologic medicines safer.

Since viral contamination poses a significant potential safety risk to patients, regulatory agencies are increasingly focusing on the use of advanced analytical technologies like NGS for detection of viral contaminants.

The new NGS-based platform can detect and identify viral contaminants within biologic compounds (such as monoclonal antibodies or vaccines) throughout the entire lifecycle of the product.

“This collaboration will provide Covance clients with a high-quality solution to the critical problem of viral contamination of biologics during development and in released product,” said Raymond Kaiser PhD, global vice president of Biopharmaceutical Chemistry, Manufacturing and Control (CMC) Solutions for Covance.

Kaiser continued, “As a cutting-edge company in the field of NGS-based virus identification, PathoQuest’s capability dovetails perfectly with our CMC analytical solutions to provide our clients access to the latest technology and patients with safer medications.”

“Covance’s global footprint and extensive experience in BioCMC development, together with their established in-house biosafety testing capabilities, offer perfect synergies to help clients access our NGS-based adventitious assay globally. In an evolving regulatory environment, we anticipate that NGS will soon become the standard approach in biosafety assessment. Our technology will help clients meet that standard now and well into the future,” said Luc Boblet PhD, co-founder and CEO of PathoQuest.

The industry is increasingly adopting the technology, with several high-profile instances of viral contamination of commercially released biologic drugs detected by NGS.

The NGS solution offered by Covance and PathoQuest overcomes the primary limitation of traditional approaches that only identify a predefined short list of viruses. In contrast, this new solution provides a universal test for identifying any virus in a single, comprehensive analysis that minimizes false negatives.

Covance and PathoQuest will provide clients with a wide range of options for adventitious virus identification. This includes a rapid detection protocol for the critical evaluation of major issues within production processes and a more comprehensive approach for development and characterization of cell banks and biological production systems.

For small, emerging and virtual biotech companies, representing a growing and valued segment of Covance’s client base, this solution allows them access to a unique technology early in the development process that will increase the value and safety profile of their molecule.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
How Did The Giraffe Get Its Long Neck?
Clues about the evolution of the giraffe’s long neck have now been revealed by new genome sequencing.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Making Genetic Data Easier to Search
Scripps team streamlines biomedical research by making genetic data easier to search.
Collaborative Study of WES Offers New Hope
Company has announced that the collaborative study of whole exome sequencing offers new hope for children with white matter disorders.
Using Portable Nanopore DNA Sequencers to Combat Wildlife Crime
University of Leicester researchers aim to develop a test using DNA to identify species at crime scenes in as little as an hour.
TGAC Installs Largest SGI UV 300 Supercomputer for Life Sciences
The Genome Analysis Centre (TGAC) partners with Global HPC hardware giant SGI to address the most complex problems in genomics analysis.
Shining A Light On Bladder Cancer
Researchers scrutinize patterns of mutations in bladder tumor genomes, gleaning insights into the roles of DNA repair and tobacco-related DNA damage.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
Five New Breast Cancer Genes Found
Discovery of mutations paves the way for personalised treatment of breast cancer.
New Neurodevelopmental Syndrome Identified
Study pinpoints underlying genetic mutations, raising hopes for targeted therapies.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!